{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-25-000159","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.259845+00:00","generated_at":"2026-05-16T22:29:31.361826+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Zentalis Q3 cash $280.7M, cuts R&D spend 37% YoY; DENALI trial on track for data by YE2026","bullets":["Cash and marketable securities $280.7M as of Sep 30, 2025; runway into late 2027.","R&D expenses $23.0M in Q3 2025, down 37.5% from $36.8M in Q3 2024.","G&A expenses $10.8M, down 26% from $14.6M YoY.","Phase 2 DENALI trial of azenosertib in Cyclin E1-positive PROC on track; topline data expected by year end 2026, potentially supporting accelerated approval.","TETON Phase 2 in USC completed enrollment; further development limited to partnering or capital allocation."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-25-000159","json":"https://secwatch.observer/filing/0001725160-25-000159.json","markdown":"https://secwatch.observer/filing/0001725160-25-000159.md","text":"https://secwatch.observer/filing/0001725160-25-000159.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000159/0001725160-25-000159-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000159/zntl-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:29:31.361826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}